Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Elm Street Ventures
AddedFeb 17, 2024
UpdatedJun 28, 2026
Elm Street Ventures

Elm Street Ventures

Operating

ESVC is a venture capital firm, creating and operating life sciences companies based on regional research, with a focus on seed and early-stage ventures.

Location
New Haven, CT, US
Founded
2006
Firm
Compare
Portfolio
Employees
Website

Elm Street Ventures (ESVC) is a venture capital firm focusing on creating and initially operating life sciences companies based on intellectual property from Yale University and other regional research institutions. The firm primarily invests in seed and early-stage ventures, leveraging its access to local, professionally managed venture capital to help scientists build significant technology companies.

Notable portfolio companies include Arvinas, Cybrexa, EvolveImmune Therapeutics, and P2 Science. ESVC's key partners are experienced serial entrepreneurs who provide strategic guidance and operational support to their portfolio companies. The firm's investment philosophy centers on fostering innovation in life sciences through close collaboration with academic institutions and leveraging regional research strengths.

Elm Street Ventures - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments22
Current Portfolio Count12
Total Portfolio Exits1

Top Investment Stages

Series A9 (40.9%)
Seed6 (27.3%)
Series Unknown4 (18.2%)
Series B2 (9.1%)
Series C1 (4.5%)

Stage Mix

Series A 41%Seed 27%Series Unknown 18%Series B 9%Series C 5%

Concentration shown as share of disclosed investments by stage.

Recent Investments

EvolveImmune Therapeutics logo

EvolveImmune Therapeutics

CellFE logo

CellFE

P2 Science logo

P2 Science

Allyx Therapeutics logo

Allyx Therapeutics

Cybrexa logo

Cybrexa

Artizan Biosciences logo

Artizan Biosciences

Halda Therapeutics logo

Halda Therapeutics

Iconic Therapeutics logo

Iconic Therapeutics

Device42 logo

Device42

Arvinas logo

Arvinas

Accelerated Orthopedic Technologies logo

Accelerated Orthopedic Technologies

Metagenomix logo

Metagenomix

Biorelix logo

Biorelix

Elm Street Ventures - Similar Investment Firms

eLab Ventures logo

eLab Ventures

elabvc.com

Accele Venture Partners logo

Accele Venture Partners

Elusive Ventures logo

Elusive Ventures

Emerald Bioventures logo

Emerald Bioventures

Royal Street Ventures logo

Royal Street Ventures

royalstreet.vc

Elizabeth Street Ventures logo

Elizabeth Street Ventures

elizabethstreet.vc

New Science Ventures logo

New Science Ventures

BioInnovation logo

BioInnovation

EVC Ventures logo

EVC Ventures

evc.ventures

Elz Ventures logo

Elz Ventures

elzventures.com

Leap Ventures logo

Leap Ventures

Avalon BioVentures logo

Avalon BioVentures

LifeSci Venture Partners logo

LifeSci Venture Partners

lifesciventure.com

Elysium Venture Capital logo

Elysium Venture Capital

Nest.Bio Venture logo

Nest.Bio Venture

nest.bio

Elm Street Ventures - Classification

Also Known As
  • ELM Street Ventures, LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 9 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 541000Professional, Scientific, and Technical Services
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 7300Business Services
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end